Company / SG&A Expense
Unicycive Therapeutics, Inc. SG&A Expense History
FY2022-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$8.5M
FY2024
5-year range
$245.0K / $8.5M
FY2022-FY2024
Trend
+30.2%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Increased from $245,000 to $9M over the past 2 years.
Based on SEC 10-K filings.
$9M in FY2024.
Increased from $245,000 to $9M over the past 2 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2024, sg&a expense increased 30.2% year-over-year.
Company context
Key Data Points
- Altman Z-Score -1.91 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $8.5M | +30.2% |
| FY2023 | $6.6M | +2580.4% |
| FY2022 | $245.0K | - |
As of FY2024 · SEC 10-K · Updated Jun 28, 2026